New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma

A 67-year-old female taking Nivolumab for melanoma developed a hyperglycemic emergency requiring hospital admission. She was referred to our endocrinology clinic post-discharge where she was diagnosed with new-onset Type 1 diabetes mellitus. Severe hyperglycemia and immune-mediated diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales: Baroud, Sarah, Mirza, Lubna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580131/
https://www.ncbi.nlm.nih.gov/pubmed/34786258
http://dx.doi.org/10.7759/cureus.18679
_version_ 1784596552987181056
author Baroud, Sarah
Mirza, Lubna
author_facet Baroud, Sarah
Mirza, Lubna
author_sort Baroud, Sarah
collection PubMed
description A 67-year-old female taking Nivolumab for melanoma developed a hyperglycemic emergency requiring hospital admission. She was referred to our endocrinology clinic post-discharge where she was diagnosed with new-onset Type 1 diabetes mellitus. Severe hyperglycemia and immune-mediated diabetes mellitus are extremely rare but potentially life-threatening side effects of Nivolumab.
format Online
Article
Text
id pubmed-8580131
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85801312021-11-15 New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma Baroud, Sarah Mirza, Lubna Cureus Endocrinology/Diabetes/Metabolism A 67-year-old female taking Nivolumab for melanoma developed a hyperglycemic emergency requiring hospital admission. She was referred to our endocrinology clinic post-discharge where she was diagnosed with new-onset Type 1 diabetes mellitus. Severe hyperglycemia and immune-mediated diabetes mellitus are extremely rare but potentially life-threatening side effects of Nivolumab. Cureus 2021-10-11 /pmc/articles/PMC8580131/ /pubmed/34786258 http://dx.doi.org/10.7759/cureus.18679 Text en Copyright © 2021, Baroud et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Baroud, Sarah
Mirza, Lubna
New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
title New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
title_full New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
title_fullStr New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
title_full_unstemmed New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
title_short New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
title_sort new-onset type 1 diabetes mellitus after treatment with nivolumab for melanoma
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580131/
https://www.ncbi.nlm.nih.gov/pubmed/34786258
http://dx.doi.org/10.7759/cureus.18679
work_keys_str_mv AT baroudsarah newonsettype1diabetesmellitusaftertreatmentwithnivolumabformelanoma
AT mirzalubna newonsettype1diabetesmellitusaftertreatmentwithnivolumabformelanoma

Ejemplares similares